Company news
Prothena Corporation plc news in 2022
Prothena Corporation plc's news releases, calls and decks from 2022, newest first.
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
December 13, 2022
Prothena Announces Proposed Public Offering of Ordinary Shares
December 12, 2022
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
November 20, 2022
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
November 2, 2022
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
October 26, 2022
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
August 31, 2022
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
August 7, 2022
Prothena to Report Second Quarter 2022 Financial Results on August 8th
July 31, 2022
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
May 4, 2022
Prothena to Report First Quarter 2022 Financial Results on May 5th
April 27, 2022
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
April 25, 2022
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
March 27, 2022
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
March 15, 2022
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights
February 16, 2022
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference Call on February 17, 2022
February 9, 2022
Calls in 2022
Decks in 2022
- Prothena Corp Public — Shareholder Meeting (April 2022)
Shareholder meeting · 16 slides · Apr 25, 2022